P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)

• Mahadeo Kris Michael,
• Baiocchi Robert,
• Beitinjaneh Amer,
• Chaganti Sridhar,
• Sylvain Choquet,
• Daan Dierickx,
• Dinavahi Rajani,
• Laurence Gamelin,
• Armin Ghobadi,
• Guzman-Becerra Norma,
• Joshi Manher,
• Mehta Aditi,
• Nikiforow Sarah,
• Reshef Ran,
• Ye Wei,
• Prockop Susan

Affiliations

Mahadeo Kris Michael

1 MD Andersen Cancer Center, Houston, United States

Baiocchi Robert

2 James Comprehensive Cancer Center, The Ohio State University, Columbus, United States

Beitinjaneh Amer

3 University of Miami/Jackson Memorial Hospital, Miami, United States

Chaganti Sridhar

4 Centre for Clinical Haematology, University Hospital Birmingham, Birmingham, United Kingdom

Sylvain Choquet

5 University Hospitals Pitié Salpêtrière - Charles Foix, Paris, France

Daan Dierickx

6 University Hospitals Leuven, Leuven, Belgium

Dinavahi Rajani

7 Atara Biotherapeutics, Thousand Oaks, United States

Laurence Gamelin

7 Atara Biotherapeutics, Thousand Oaks, United States

Armin Ghobadi

8 Washington University, Division of Oncology, Saint Louis, United States

Guzman-Becerra Norma

9 Atara Biotherapeutics, South San Francisco, United States

Joshi Manher

9 Atara Biotherapeutics, South San Francisco, United States

Mehta Aditi

7 Atara Biotherapeutics, Thousand Oaks, United States

Nikiforow Sarah

10 Dana-Farber Cancer Institute, Boston, United States

Reshef Ran

11 Columbia University Medical Center, New York, United States

Ye Wei

9 Atara Biotherapeutics, South San Francisco, United States

Prockop Susan

12 Boston Children’s Hospital/Dana Farber Cancer Institute, Boston, United States